Key result
Intracardiac VEGF-A mRNA improves post-MI LVEF by ~5 percentage points over vehicle in preclinical models.
Why the study?
Does intracardiac injection of purified VEGF-A 165 mRNA in a citrate-saline buffer 1 week post-myocardial infarction improve left ventricular ejection fraction and limit myocardial damage in a swine model of permanent LAD occlusion?
Does intracardiac injection of purified VEGF-A 165 mRNA in a citrate-saline buffer 1 week post-myocardial infarction improve left ventricular ejection fraction and limit myocardial damage in a swine model of permanent LAD occlusion?
Intracardiac delivery of purified, carrier-free VEGF-A mRNA in citrate-saline 1 week after myocardial infarction safely improves systolic function, promotes border-zone neovascularization, and reduces fibrosis in swine, supporting clinical translation.
Answers are grounded in this paper and cite their sources.
Preclinical and should not yet change practice; leaves open whether intracardiac VEGF-A mRNA translates to safe, clinically meaningful LVEF recovery in human post-MI trials.
mRNA can direct dose-dependent protein expression in cardiac muscle without genome integration, but to date has not been shown to improve cardiac function in a safe, clinically applicable way. Herein, we report that a purified and optimized mRNA in a biocompatible citrate-saline formulation is tissue specific, long acting, and does not stimulate an immune response. In small- and large-animal, permanent occlusion myocardial infarction models, VEGF-A 165 mRNA improves systolic ventricular function and limits myocardial damage. Following a single administration a week post-infarction in mini pigs, left ventricular ejection fraction, inotropy, and ventricular compliance improved, border zone arteriolar and capillary density increased, and myocardial fibrosis decreased at 2 months post-treatment. Purified VEGF-A mRNA establishes the feasibility of improving cardiac function in the sub-acute therapeutic window and may represent a new class of therapies for ischemic injury.
No takes yet. Share an insight, caveat, or question.
Carlsson et al. (2018) studied Sub-acute myocardial infarction (permanent LAD occlusion model) (n=29). Purified human VEGF-A 165 mRNA in citrate-saline formulation (cs-VEGF mRNA) vs. Citrate-saline vehicle intracardiac injection (and sham surgery group) was evaluated on Left ventricular ejection fraction (LVEF) at 2 months post-treatment in swine (p=<0.05). Intracardiac purified VEGF-A mRNA 1 week post-MI improved LVEF at 2 months in mini pigs to 51% and with vehicle.
Synapse has enriched 10 related papers. Consider them for comparative context: